UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT06279026
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
BIOLOGICAL:
UTAA17 Injection
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators
[object Object]